Key Event Title
|Level of Biological Organization|
Key Event Components
Key Event Overview
AOPs Including This Key Event
|AOP Name||Role of event in AOP|
|NR1I3 suppression to steatosis||AdverseOutcome|
|PXR activation to steatosis||AdverseOutcome|
|NRF2/FXR to steatosis||AdverseOutcome|
|AKT2 activation to steatosis||AdverseOutcome|
|Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis||AdverseOutcome|
|Inhibition fatty acid beta oxidation leading to nonalcoholic steatohepatisis (NASH)||KeyEvent|
|All life stages||High|
Key Event Description
Biological state: liver steatosis is the inappropriate storage of fat in hepatocytes.
Biological compartment: steatosis is generally an organ-level diagnosis; however, the pathology occurs within the hepatocytes.
Role in biology: steatosis is an adverse endpoint.
How It Is Measured or Detected
Steatosis is measured by lipidomics approaches that measure lipid levels, or by histology.
Domain of Applicability
Steatosis is the result of perturbations in well-known metabolic pathways that are well-studied and well-known in many taxa.
Regulatory Significance of the Adverse Outcome
Steatosis is a regulatory endpoint and has been used as an endpoint in many US EPA assessments, including IRIS assessments.